But the renal toxicity of adefovir, long-term safety of entecavir and cross-resistance between emtricitabine and lamivudine should do further observation be...

• 但是阿得福韦的肾毒性,恩替卡韦的长期安全性和依曲西他平与拉米夫定的交叉耐药性在正式批准临床应用阶段需作进一步的观察。